ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1436

TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis

Hiroaki Hayashi, Takafumi Harada, Shunsuke Demizu, Fumito Tatsuzawa, Ken Sato, Morihiro Mitsuya, Kenji Tanaka, Kazuhiko Yonekura, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: animal models and small molecules, Janus kinase (JAK), kinase, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Animal Models - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   The family of Janus kinases (JAKs) plays important roles in signaling pathway mediated by various cytokine receptors. An aberrant activation of JAK-STAT signaling has been reported to be involved in the pathogenesis of autoimmune diseases.Non-selective JAK inhibitors have shown excellent efficacy in patient with rheumatoid arthritis (RA). However, their use is limited due to adverse effects and safety concerns by inhibiting JAK1/2 signaling. Selective inhibition of JAK3 might result in an improved safety profile while maintaining excellent efficacy. The objectives of this study were to identify pharmacological profiles of TAS8274, a novel JAK3 inhibitor with high selectivity, and to evaluate its therapeutic potential in rat adjuvant-induced arthritis (AIA).

Methods:   In vitro biochemical assay was performed using available kinase assay panels. In cell-based assay, JAK3 activation was evaluated by interleukin (IL) -2-induced human peripheral blood mononuclear cells (PBMC) proliferation. IL-2–, IFN-α– and IL-3–induced phosphorylation of STAT proteins in PBMC were analyzed and quantified by a flow cytometry-based assay. Female Lewis rats were injected intradermally with adjuvant at the base of the tail. In order to evaluate the therapeutic efficacy of TAS8274 in rat AIA, treatment was initiated when the overt clinical signs of disease were observed. TAS8274 was administered orally twice daily for 2 weeks. Swelling in hind paws were measured using a plethysmometer. At the end of the experiment, the paws were removed to analyze the histopathological changes. The scoring of inflammation, pannus, cartilage and bone damage in two joints of the rat AIA was performed by a single blinded pathologist using a modified Mankin score system.

Results:   TAS8274 strongly inhibited the enzymatic activity of JAK3, and showed more than 1000-fold selectivity against other JAK family members, JAK1, JAK2 and TYK2. TAS8274 inhibited the IL-2–induced proliferation of PBMC in a dose dependent manner (IC50 = 25.3 nM) and also potently suppressed IL-2–induced STAT5 phosphorylation (IC50 = 18.9 nM). On the other hand, TAS8274 showed 300-3000 fold less inhibitory effects against JAK3–independent IFN-α or IL-3–induced STAT phosphorylation than that of JAK3–dependent STAT phosphorylation. In an established rat AIA, the hind paw volume in TAS8274-treated rats was dose-dependently decreased after oral administration of TAS8274 (0.3 to 10 mg/kg). TAS8274 also significantly reduced paw histopathology scores compared with those in vehicle-treated rats.

Conclusion:   Our results demonstrate that TAS8274 has the potential to elicit JAK3-mediated immunomodulatory effects without affecting the activities of JAK1, JAK2 and TYK2 and improves clinical signs of arthritis in the rat AIA. TAS8274 would be an attractive therapeutic agent for patients with autoimmune disorders such as RA, and reduce the side effects induced by inhibiting other JAK family members. TAS8274 was selected as a clinical candidate and is being evaluated for its safety profile to initiate Phase 1 study.


Disclosure: H. Hayashi, None; T. Harada, None; S. Demizu, None; F. Tatsuzawa, None; K. Sato, None; M. Mitsuya, None; K. Tanaka, None; K. Yonekura, None; T. Utsugi, None; E. Sasaki, None; Y. Iwasawa, None.

To cite this abstract in AMA style:

Hayashi H, Harada T, Demizu S, Tatsuzawa F, Sato K, Mitsuya M, Tanaka K, Yonekura K, Utsugi T, Sasaki E, Iwasawa Y. TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tas8274-a-highly-selective-janus-kinase-3-inhibitor-demonstrates-potent-efficacy-in-an-animal-model-of-rheumatoid-arthritis/. Accessed March 7, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tas8274-a-highly-selective-janus-kinase-3-inhibitor-demonstrates-potent-efficacy-in-an-animal-model-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.